Cancer Research 20 February 2026 - 24 May 2026

Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus
····

Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus

Legend Biotech shares fell 3.89% Friday to $27.16, down 7.5% for the week, ahead of a Sunday investor event at the ASCO cancer conference. The company plans to present early Phase 1 data for its experimental CAR-T therapy LB2102 and updates on CARVYKTI. Investors are watching for potential stock movement when markets reopen Monday. CARVYKTI sales rose 62% year-on-year to $597 million in Q1.
May 31, 2026
NovoCure Stock Still Up Ahead of Cancer Trial Data
····

NovoCure Stock Still Up Ahead of Cancer Trial Data

NovoCure shares closed at $17.96 Friday, up 0.3%, and slipped to $17.71 after hours ahead of the Memorial Day market closure. The stock remains about 50% above its April 29 close, after the company raised its 2026 revenue forecast and reported Q1 revenue of $174.1 million. NovoCure had 4,791 active patients at March’s end, including 83 on its new pancreatic cancer device.
May 24, 2026
Caribou Biosciences Holds Near $2 With June Cancer Drug Updates Ahead
····

Caribou Biosciences Holds Near $2 With June Cancer Drug Updates Ahead

Caribou Biosciences shares rose about 1% to $2.01 on Friday ahead of cancer drug data updates expected in June. The company plans to present new results on vispa-cel and CB-011 at the European Hematology Association meeting. Caribou had $118.6 million in cash at March 31 and raised $2.3 million by selling 1.08 million shares in the first quarter. The stock traded before a three-day U.S. market holiday.
May 22, 2026
Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3
····

Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3

Relmada Therapeutics will raise about $160 million in a private placement, priced at $4.75 a share, after reporting 12-month data showing a 76% complete response rate for NDV-01 in non-muscle invasive bladder cancer. The financing, expected to close by March 11, follows FDA feedback backing late-stage studies. NDV-01 showed no cases of disease progression or severe side effects among 25 patients at 12 months.
March 9, 2026
Grail stock plunges almost 50% after NHS trial misses key goal for Galleri cancer test
···

Grail stock plunges almost 50% after NHS trial misses key goal for Galleri cancer test

Grail shares plunged 49.5% to $51.26 by midday Friday after its NHS-Galleri trial missed the primary endpoint of reducing stage III-IV cancers. The company said it would extend follow-up and submit results to ASCO. Over 10 million shares traded. Galleri’s FDA approval process continues, but analysts flagged uncertainty over insurance coverage.
February 20, 2026